Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study.

Abstract

OBJECTIVE:

To study the efficacy of anakinra versus disease-modifying antirheumatic drugs (DMARD) in refractory adult-onset Still's disease (AOSD).

METHODS:

In a 24-week study, 22 patients with AOSD taking prednisolone ≥ 10 mg/day received anakinra (n = 12) or DMARD (n = 10). The primary endpoint was achievement of remission.

RESULTS:

At 8 and 24 weeks, 7/12 and 6/12 receiving anakinra and 5/10 and 2/10 receiving DMARD achieved remission. Anakinra induced greater improvement in physical health measured by Medical Outcomes Study Short-Form 36 (SF-36; p < 0.011). During an open-label extension (OLE) of 28 weeks, 7/14 patients taking anakinra and 2/3 taking DMARD were in remission.

CONCLUSION:

Anakinra induced more beneficial responses than DMARD in patients with AOSD and was favored in the OLE phase. (ClinicalTrials.gov Protocol Registration NCT01033656).

• Authors: Dan Nordström, Ann Knight, Reijo Luukkainen, Ronald van Vollenhoven, Vappu Rantalaiho, Anna Kajalainen, Johan G Brun, Anne Proven, Lotta Ljung, Hannu Kautiainen, Tom Pettersson
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 39 Issue 10 Pg. 2008-11 (Oct 2012) ISSN: 0315-162X [Print] Canada
• PMID: 22859346 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antirheumatic Agents
• Interleukin 1 Receptor Antagonist Protein
• Isoxazoles
• Receptors, Interleukin-1
• Sulfasalazine
• Leflunomide
• Azathioprine
• Methotrexate

Topics

• Adult
• Antirheumatic Agents (therapeutic use)
• Azathioprine (therapeutic use)
• Female
• Humans
• Interleukin 1 Receptor Antagonist Protein (therapeutic use)
• Isoxazoles (therapeutic use)
• Leflunomide
• Male
• Methotrexate (therapeutic use)
• Middle Aged
• Receptors, Interleukin-1 (antagonists & inhibitors)
• Remission Induction
• Still's Disease, Adult-Onset (drug therapy)
• Sulfasalazine (therapeutic use)
• Treatment Outcome